Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2021

May 14, 2021

SELL
$4.86 - $13.07 $65,021 - $174,863
-13,379 Closed
0 $0
Q4 2020

Jun 22, 2023

BUY
$9.48 - $12.84 $126,832 - $171,786
13,379 New
13,379 $169,000
Q3 2020

Jun 26, 2023

BUY
$8.67 - $10.82 $115,995 - $144,760
13,379 New
13,379 $131,000
Q2 2020

May 24, 2024

BUY
$7.8 - $11.52 $104,356 - $154,126
13,379 New
13,379 $133 Million
Q2 2020

Jun 26, 2023

BUY
$7.8 - $11.52 $104,356 - $154,126
13,379 New
13,379 $133,000
Q1 2020

Jul 12, 2023

BUY
$5.98 - $13.09 $80,006 - $175,131
13,379 New
13,379 $118,000
Q1 2020

Mar 22, 2023

BUY
$5.98 - $13.09 $26,347 - $57,674
4,406 Added 49.1%
13,379 $118,000
Q1 2020

May 15, 2020

BUY
$5.98 - $13.09 $80,006 - $175,131
13,379 New
13,379 $118,000
Q4 2019

Feb 14, 2020

SELL
$5.71 - $9.22 $51,235 - $82,731
-8,973 Closed
0 $0
Q3 2019

Jul 12, 2023

BUY
$5.88 - $12.35 $52,761 - $110,816
8,973 New
8,973 $52,000
Q2 2019

Jul 12, 2023

BUY
$9.44 - $13.12 $84,705 - $117,725
8,973 New
8,973 $107,000
Q1 2019

Jul 13, 2023

BUY
$12.07 - $17.54 $108,304 - $157,386
8,973 New
8,973 $108,000
Q4 2018

Jul 13, 2023

BUY
$11.25 - $16.17 $100,946 - $145,093
8,973 New
8,973 $112,000
Q4 2018

Mar 22, 2023

SELL
$11.25 - $16.17 $56,025 - $80,526
-4,980 Reduced 35.69%
8,973 $112,000
Q4 2018

Feb 14, 2019

SELL
$11.25 - $16.17 $56,025 - $80,526
-4,980 Reduced 35.69%
8,973 $113,000
Q3 2018

Jul 13, 2023

BUY
$12.82 - $17.88 $115,033 - $160,437
8,973 New
8,973 $133,000
Q3 2018

Mar 22, 2023

BUY
$12.82 - $17.88 $178,877 - $249,479
13,953 New
13,953 $207,000
Q3 2018

Nov 14, 2018

BUY
$12.82 - $17.88 $63,843 - $89,042
4,980 Added 55.5%
13,953 $207,000
Q4 2017

Feb 15, 2018

BUY
$13.96 - $29.05 $125,263 - $260,665
8,973
8,973 $232,000

Others Institutions Holding CNCE

# of Institutions
1
Shares Held
0
Call Options Held
0
Put Options Held
0

About CONCERT PHARMACEUTICALS, INC.


  • Ticker CNCE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 47,934,600
  • Description
  • Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company that develops novel small molecule drugs for the treatment of autoimmune diseases. The company's lead product candidate is CTP-543, which is in Phase III clinical trial for the treatment of alopecia areata, a serious autoimmune dermatological condition. It has s...
More about CNCE
Track This Portfolio

Track Met Life Investment Management, LLC Portfolio

Follow Met Life Investment Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Met Life Investment Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Met Life Investment Management, LLC with notifications on news.